Project Grant R01CA299421
Award Date
2/24/25
Completion Date
1/31/30
Dollars Obligated
$654K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This $471,675 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund research at Oregon Health & Science University to develop a nanoparticle-based blood test to distinguish pancreatic cancer from benign pancreatic disease. The researchers will use high conductance dielectrophoresis technology to simultaneously recover different types of cancer-derived...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $1,199,514 to develop a comprehensive and scalable risk prediction model, termed "PRECISE", that fuses imaging and non-imaging data to enable early detection of pancreatic ductal adenocarcinoma (PDAC) in asymptomatic individuals. Key objectives include:
Developing deep learning models to segment imaging biomarkers from abdominal CT scans, applying...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $263,086 to the Sloan-Kettering Institute for Cancer Research to develop a multiparametric endoscopic ultrasound (MPEUS) imaging system for improved pancreatic cancer screening and characterization.
The key objectives are to implement real-time MPEUS imaging, which combines B-mode, ultrasensitive microvessel imaging, shear-wave elastography, and quantitative...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,615,866 in funding to The Regents of the University of California, San Francisco (UCSF) to develop and validate a two-tier classifier for identifying advanced neoplasia in pancreatic cystic lesions. The project aims to refine target proteins and proteomics-based biomarkers to improve the detection and diagnosis of high-grade dysplasia or invasive pancreatic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $622,984 to the University of California, Los Angeles (UCLA) to conduct a multi-year systems metabolic approach for characterizing and imaging pancreatic cancer phenotypes. The key objectives are to:
Integrate multi-scale measurements from cell, tissue, and organ levels with advanced imaging modalities (PET/CT) to establish definitive phenotypes of pancreatic...
The Johns Hopkins University was awarded a $431,561 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research aimed at elucidating the role of the HMGA1 chromatin regulator in pancreatic ductal adenocarcinoma (PDAC) progression and the tumor microenvironment (TME). The research project seeks to precisely define HMGA1-dependent mechanisms in PDAC tumor progression using mouse models and primary human tumors, as well as...
The National Cancer Institute (NCI) awarded The Johns Hopkins University a $432,889 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct innovative research on reversing pancreatic cancer-induced cachexia. The five-year project aims to apply molecular and functional imaging capabilities, as well as theranostic nanoparticle technologies, to target the glutamine/glutamate axis and disrupt glutamine metabolism in preclinical pancreatic cancer models....
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), is focused on the development of a theragnostic radiopharmaceutical for the treatment of pancreatic cancer. The key products and services to be delivered include:
The project aims to identify and optimize peptide ligands that target the claudin-4 (CLDN4) protein, which is overexpressed in pancreatic adenocarcinoma. These peptides will be evaluated for...
This Cooperative Agreement award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $585,458 to validate a mass spectrometry-based proteomic assay for early detection of pancreatic cancer. The project aims to: 1) determine the performance characteristics and robustness of the assay for clinical use; 2) refine the assay's accuracy and thresholds for pancreatic cancer detection using well-annotated case-control cohorts; and 3) evaluate...
This Project Grant award of $145,000 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research on the role of the JMJD4 enzyme in pancreatic cancer. The overarching goal is to advance the mechanistic understanding of how JMJD4 functions and its potential as a novel target for pancreatic cancer treatment.
Specifically, the research will (1) determine the role of JMJD4 in pancreatic cancer cells, and (2) reveal how JMJD4 acts at the...